Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

PURPOSE: Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising therapies for advanced non-small cell lung cancer (NSCLC). Our study was aimed to determine whether there were condi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Chemother Pharmacol
Hlavní autoři: Li, Heyan, Takayama, Koichi, Wang, Shuo, Shiraishi, Yoshimasa, Gotanda, Keisuke, Harada, Taishi, Furuyama, Kazuto, Iwama, Eiji, Ieiri, Ichiro, Okamoto, Isamu, Nakanishi, Yoichi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236614/
https://ncbi.nlm.nih.gov/pubmed/25344762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2610-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky